fillwise.fillwise.

Look up one drug

Ontario coverage, price, criteria word for word, Health Canada status and shortages for one product

Medication plan: estimated costs for a whole medication list

Private plan not entered. Private-plan coverage, and how it coordinates with public programs, is not determined here; the Ontario public-program lines on this page remain conditional on the entered details and the program rules.

Faricimab

All strengths: Limited Use, Reason for Use code 649, 650, 725 required; same patient cost rules

Shared coverage and patient cost rules
StatusLimited Use, Reason for Use code 649, 650, 725 required
Patient paysIf the Reason for Use code is written and the criteria are met, ODB 65 and over pays: • ODB senior: $100/program-year deductible • Then up to $6.11 per prescription • Or, if enrolled in the Seniors Co-Payment Program (income-tested; individual net income below $25,480 for Aug 2026–Jul 2027): no deductible, up to $2 per prescription If the criteria are not met, ODB does not pay this product under Limited Use. [Limited Use benefit, Formulary flag]

Vabysmo · DIN 02554003 · 6 mg/0.05 mL · injection, 0.05 mL pre-filled syringe (preservative-free)

Limited Use, Reason for Use code 649, 650, 725 requiredMarketed · checked October 5, 2026
Write on scriptone applicable Reason for Use code, 649 or 650 or 725 (criteria below)
Ontario Limited Use criteria, code 649, 650, 725
Reason for Use code 649 For the treatment of patients with neovascular (wet) age-related macular degeneration (AMD) in a treatment-naive eye. Initial diagnosis should be confirmed by an appropriate diagnostic procedure and administration should be done by a qualified ophthalmologist experienced in intravitreal injections. Patients receiving concurrent administration of verteporfin PDT (Visudyne), ranibizumab (Lucentis), aflibercept (Eylea) or brolucizumab (Beovu) are not eligible for reimbursement. Treatment should be initiated with an intravitreal injection every 4 weeks for the first 4 doses, followed by one injection every 8 to 16 weeks based upon disease activity. Treatment with anti-VEGF agents should only be continued in patients who maintain adequate response to therapy. For clarity, coverage will be provided for patients responding to therapy with another anti-VEGF agent who switch to Vabysmo. Coverage will NOT be provided for patients who have failed to respond to other anti-VEGF agents. Coverage limit: LU Authorization Period: 1 year Reason for Use code 650 For the treatment of patients with clinically significant diabetic macular edema (DME) for whom laser photocoagulation is also indicated; and who have a hemoglobin A1c of less than 12 percent. Vabysmo is to be administered using one of the following dosing regimens: Treatment should be initiated with an intravitreal injection every 4 weeks for the first 6 doses, followed by an intravitreal injection at a dosing interval of every 8 weeks. OR Treatment should be initiated with an intravitreal injection every 4 weeks for the first 4 doses or until macular edema is resolved. Thereafter, the dosing interval may be extended up to every 16 weeks (4 months) in up to 4-week increments. If anatomic and/or visual outcomes deteriorate, then the treatment interval should be shortened accordingly. Treatment with anti-VEGF agents should only be continued in patients who maintain adequate response to therapy. For clarity, coverage will be provided for patients responding to therapy with another anti-VEGF agent who switch to Vabysmo. Coverage will NOT be provided for patients who have failed to respond to other anti-VEGF agents. Coverage limit: LU Authorization Period: 1 year Reason for Use code 725 For the treatment of patients with clinically significant macular edema secondary to branch retinal vein occlusion (BRVO) or central retinal vein occlusion (CRVO). Treatment should be initiated with an intravitreal injection every 4 weeks until stable visual acuity improvement and disease control are achieved. The treatment interval may be extended up to 16 weeks (4 months) in up to 4-week increments at a time in patients without disease activity. If anatomic and/or visual outcomes deteriorate, the treatment interval should be shortened accordingly. The interval between doses should not be shorter than one month. Patients should be assessed regularly. Treatment with anti-VEGF agents should only be continued in patients who maintain adequate response to therapy. For clarity, coverage will be provided for patients responding to therapy with another anti-VEGF agent who switch to this product. Coverage will NOT be provided for patients who have failed to respond to other anti-VEGF agents. Coverage limit: LU Authorization Period: 1 year
No interchangeable product listed in the Ontario extract
Vabysmo · DIN 02554003 Manufacturer: Hoffmann-La Roche Limited; listing date 2025-10-31 Health Canada: Marketed since 2025-06-30 · brand VABYSMO · ATC S01LA09 FARICIMAB · form Solution · route Intravitreal · ingredients FARICIMAB 6 MG/0.05ML · company Hoffmann-la roche limited · schedule Schedule d, Prescription
Re-check Health Canada status and shortages (live) · Health Canada product record

Vabysmo: Formulary list price $1350.00 per unit (the source does not state the unit; exact figure $1350.0000). What the ministry pays, not the patient.

Formulary data: Ontario extract of September 22, 2026 · Health Canada DPD extract of October 5, 2026 (Open Government Licence – Canada) · Health Canada DPD page · Verify on the e-Formulary ↗ (DIN 02554003)

Source record
DIN 02554003: Vabysmo Raw flags: sec12=Y, sec3=Y Item: 523600159; group id 625; item number 1593; lccId 00371; manufacturer id HLR Source form: Inj Sol-0.05mL Pref Syr (Preservative-Free); strength: 6mg/0.05mL Recorded listing: Limited Use: paid only with a Reason for Use code and the criteria below Source prices (unrounded): $1350.0000; ministry $1350.0000 Source: ODB odb-formulary-ed43-extract-2026-09-22.xml extract_date=September 22, 2026 DIN=02554003 Health Canada DPD extract of October 5, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=104289
Shortage status: no shortage or discontinuation reported (checked October 6, 2026); reports as of October 6, 2026 (Health Product Shortages Canada) Source: https://healthproductshortages.ca/search?term=02554003
Shortage record checked October 6, 2026

Vabysmo · DIN 02527618 · 6 mg/0.05 mL · injection solution-0.24mL vial (Preservative-Free)

Limited Use, Reason for Use code 649, 650, 725 requiredMarketed · checked October 5, 2026
Write on scriptone applicable Reason for Use code, 649 or 650 or 725 (criteria below)
Ontario Limited Use criteria, code 649, 650, 725
Reason for Use code 649 For the treatment of patients with neovascular (wet) age-related macular degeneration (AMD) in a treatment-naive eye. Initial diagnosis should be confirmed by an appropriate diagnostic procedure and administration should be done by a qualified ophthalmologist experienced in intravitreal injections. Patients receiving concurrent administration of verteporfin PDT (Visudyne), ranibizumab (Lucentis), aflibercept (Eylea) or brolucizumab (Beovu) are not eligible for reimbursement. Treatment should be initiated with an intravitreal injection every 4 weeks for the first 4 doses, followed by one injection every 8 to 16 weeks based upon disease activity. Treatment with anti-VEGF agents should only be continued in patients who maintain adequate response to therapy. For clarity, coverage will be provided for patients responding to therapy with another anti-VEGF agent who switch to Vabysmo. Coverage will NOT be provided for patients who have failed to respond to other anti-VEGF agents. Coverage limit: LU Authorization Period: 1 year Reason for Use code 650 For the treatment of patients with clinically significant diabetic macular edema (DME) for whom laser photocoagulation is also indicated; and who have a hemoglobin A1c of less than 12 percent. Vabysmo is to be administered using one of the following dosing regimens: Treatment should be initiated with an intravitreal injection every 4 weeks for the first 6 doses, followed by an intravitreal injection at a dosing interval of every 8 weeks. OR Treatment should be initiated with an intravitreal injection every 4 weeks for the first 4 doses or until macular edema is resolved. Thereafter, the dosing interval may be extended up to every 16 weeks (4 months) in up to 4-week increments. If anatomic and/or visual outcomes deteriorate, then the treatment interval should be shortened accordingly. Treatment with anti-VEGF agents should only be continued in patients who maintain adequate response to therapy. For clarity, coverage will be provided for patients responding to therapy with another anti-VEGF agent who switch to Vabysmo. Coverage will NOT be provided for patients who have failed to respond to other anti-VEGF agents. Coverage limit: LU Authorization Period: 1 year Reason for Use code 725 For the treatment of patients with clinically significant macular edema secondary to branch retinal vein occlusion (BRVO) or central retinal vein occlusion (CRVO). Treatment should be initiated with an intravitreal injection every 4 weeks until stable visual acuity improvement and disease control are achieved. The treatment interval may be extended up to 16 weeks (4 months) in up to 4-week increments at a time in patients without disease activity. If anatomic and/or visual outcomes deteriorate, the treatment interval should be shortened accordingly. The interval between doses should not be shorter than one month. Patients should be assessed regularly. Treatment with anti-VEGF agents should only be continued in patients who maintain adequate response to therapy. For clarity, coverage will be provided for patients responding to therapy with another anti-VEGF agent who switch to this product. Coverage will NOT be provided for patients who have failed to respond to other anti-VEGF agents. Coverage limit: LU Authorization Period: 1 year
No interchangeable product listed in the Ontario extract
Vabysmo · DIN 02527618 Manufacturer: Hoffmann-La Roche Limited; listing date 2023-06-30 Health Canada: Marketed since 2022-07-18 · brand VABYSMO · ATC S01LA09 FARICIMAB · form Solution · route Intravitreal · ingredients FARICIMAB 6 MG/0.05ML · company Hoffmann-la roche limited · schedule Schedule d, Prescription
Re-check Health Canada status and shortages (live) · Health Canada product record

Vabysmo: Formulary list price $1350.00 per unit (the source does not state the unit; exact figure $1350.0000). What the ministry pays, not the patient.

Formulary data: Ontario extract of September 22, 2026 · Health Canada DPD extract of October 5, 2026 (Open Government Licence – Canada) · Health Canada DPD page · Verify on the e-Formulary ↗ (DIN 02527618)

Source record
DIN 02527618: Vabysmo Raw flags: sec12=Y, sec3=Y Item: 523600150; group id 625; item number 1594; lccId 00371; manufacturer id HLR Source form: Inj Sol-0.24mL Vial Pk (Preservative-Free); strength: 6mg/0.05mL Recorded listing: Limited Use: paid only with a Reason for Use code and the criteria below Source prices (unrounded): $1350.0000; ministry $1350.0000 Source: ODB odb-formulary-ed43-extract-2026-09-22.xml extract_date=September 22, 2026 DIN=02527618 Health Canada DPD extract of October 5, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=101666
Shortage status: no shortage or discontinuation reported (checked October 6, 2026); reports as of October 6, 2026 (Health Product Shortages Canada) Source: https://healthproductshortages.ca/search?term=02527618
Shortage record checked October 6, 2026

Other products in the same Health Canada class (S01LA): coverage varies; not interchangeable

  • Aflibercept (Aflivu): limited Use 694, 695, limited Use 729, 730, 731
  • Brolucizumab (Beovu): limited Use 620, 648
  • Ranibizumab (Byooviz): limited Use 651, 652, 653, 654
Other drugs in the same formulary class (52:36 Other Eye, Ear, Nose and Throat Agents) and how they are covered

Matched class: 52:36 Other Eye, Ear, Nose and Throat Agents

Drug-class inventory only. Lists recorded Ontario formulary products, not every Canadian medication; does not recommend treatment. Public program routes: ODB 65 and over Covered without a code on the Ontario formulary: BETAXOLOL HCL, DICLOFENAC SODIUM, LEVOBUNOLOL HCL Some products covered without a code (check the product listing): ACETAZOLAMIDE, METHAZOLAMIDE, SODIUM CROMOGLYCATE, TIMOLOL MALEATE 52:36 Other Eye, Ear, Nose and Throat Agents

AFLIBERCEPT

· 6 products · Limited Use, codes 729, 730, 731 (4), Limited Use, codes 694, 695 (2) · strengths: 2mg/0.05mL, 8mg/0.07mL · Inj Sol-0.05mL Pref Syr (Preservative-Free), Inj Sol-0.07mL Pref Syr, Inj Sol-0.07mL Vial Pk, Sol for Intravitreal Inj-0.05mL Vial Pk

BROLUCIZUMAB

· 1 products · Limited Use, codes 620, 648 · strengths: 6mg/0.05mL · Inj Sol-0.05mL Pref Syr (Preservative-Free)

RANIBIZUMAB

· 2 products · Limited Use, codes 651, 652, 653, 654 · strengths: 10mg/mL · Inj Sol-0.23mL Vial Pk (Preservative-Free)

ACETAZOLAMIDE

· 2 products · General benefit (1), Listed, not a benefit (1) · strengths: 250mg · Tab

BETAXOLOL HCL

· 1 products · General benefit · strengths: 0.25% · Oph Susp

DICLOFENAC SODIUM

· 6 products · General benefit · strengths: 0.1% · Oph Sol

LEVOBUNOLOL HCL

· 1 products · General benefit · strengths: 0.5% · Oph Sol

METHAZOLAMIDE

· 2 products · Listed, not a benefit (1), General benefit (1) · strengths: 50mg · Tab

SODIUM CROMOGLYCATE

· 2 products · General benefit (1), Listed, not a benefit (1) · strengths: 2% · Oph Sol

TIMOLOL MALEATE

· 10 products · Listed, not a benefit (2), General benefit (8) · strengths: 0.25%, 0.5% · Oph Gellan Sol, Oph Sol

BIMATOPROST

· 8 products · Listed, not a benefit (1), Limited Use, codes 171, 172, 387 (7) · strengths: 0.03%, 0.01% · Oph Sol, Oph Sol-5mL Pk, Oph Sol-7.5mL Pk

BRIMONIDINE

· 7 products · Limited Use, codes 171, 172, 387 · strengths: 0.15%, 0.2% · Oph Sol Source: formulary-ed43-front-matter.txt Part V; ODB odb-formulary-ed43-extract-2026-09-22.xml extract_date=2026-09-22; class 52:36 and 20 more
Full class listing Related classes: 52:04 Anti-Infectives, 52:08 Anti-Inflammatory Agents, 52:16 Local Anesthetics, 52:20 Miotics, 52:24 Mydriatics, 52:32 Vasoconstrictors Same formulary class, not same indication: class membership alone does not establish equivalent uses.
What the Health Canada label says it is for
1. Indications VABYSMO (faricimab injection) is indicated for the treatment of: • Neovascular (wet) age-related macular degeneration (AMD) • Diabetic macular edema (DME) • Macular edema secondary to retinal vein occlusion (RVO) 1.1. Pediatrics Pediatrics (< 18 years of age): No data are available to Health Canada; therefore, Health Canada has not authorized an indication for pediatric use. 1.2. Geriatrics Geriatrics (≥ 65 years of age): No dose adjustment is required in patients ≥ 65 years of age (see 4.2 Recommended Dose and Dosage Adjustment, Special Populations and 10.3 Pharmacokinetics, Special populations and conditions). https://pdf.hres.ca/dpd_pm/00081239.PDF PM date: Road 25, 2025 Source product: VABYSMO; DIN 02527618; fetched 2026-09-10 Product monograph posted by Health Canada; excerpt for lookup only.
Program rules and quotes
Public program routes (Ontario context; residency, health-card/OHIP requirements and enrolment must be confirmed from the quoted rules): ODB 65 and over (seniors path) Eligibility: You may qualify for the Ontario Drug Benefit (ODB) program when you turn 65 years old. (ontario.ca, August 18, 2026 ↗) Eligibility: The Ontario Drug Benefit program is for Ontario residents only and prescriptions must be filled in an Ontario pharmacy to be covered. (ontario.ca, August 18, 2026 ↗) Eligibility: Individual annual net income threshold Program year August 1, 2026 to July 31, 2027: $25,480 This applies to a senior who: does not have a spouse has a married spouse with whom they no longer live in a conjugal relationship has a spouse living in a long-term care home or community home for opportunity (ontario.ca, July 2, 2026 ↗) Eligibility: Combined annual net income requirement Program year August 1, 2026 to July 31, 2027: $42,290 This applies to a senior who has a spouse, other than a spouse described. (ontario.ca, July 2, 2026 ↗) Eligibility: See the first-year deductible table. (ontario.ca, August 18, 2026 ↗) What it pays / costs: the first $100 of total prescription costs each program year (August 1 to July 31 the following year) (ontario.ca, August 18, 2026 ↗) What it pays / costs: up to $6.11 for each prescription filled or refilled (after paying the deductible) (ontario.ca, August 18, 2026 ↗) What it pays / costs: Seniors enrolled in the Seniors Co-Payment Program have no annual deductible and a reduced co-payment of up to $2. (ontario.ca, August 18, 2026 ↗) Enrolment: "We will send you a letter about 3 months before your 65th birthday to let you know you will automatically join the Ontario Drug Benefit program on the first day of the month after you turn 65 years old." (ontario.ca, August 18, 2026 ↗) Enrolment: "To enroll in the Seniors Co-Payment Program, a senior must submit an application to that program and qualify under certain income eligibility thresholds." (ontario.ca, August 18, 2026 ↗)
First year on ODB? The deductible depends on birth month
For your first year of Ontario Drug Benefit program eligibility, depending on the month you turn 65, the deductible may be lower than $100. That’s because the amount of the deductible is based on the number of months between your official start date (the first day of the month after you turn 65) and July 31 (the last day of the Ontario Drug Benefit program year). For example, if you turned 65 on April 15, your official start date would be May 1. Counting from May 1 to July 31 your deductible for the first year would be $25. Use this chart below to see what the deductible will be in your first year:
Month you were bornAmount of first-year deductible
July$100.00
August$91.67
September$83.33
October$75.00
November$66.67
December$58.33
January$50.00
February$41.67
March$33.33
April$25.00
May$16.67
June$8.33

Ontario source · 2026-08-18